| Drug Name: | MK-801 (77086-21-6) |
|---|---|
| PubChem ID: | 180081 |
| SMILES: | C[C@@]12C3=CC=CC=C3C[C@@H](N1)C4=CC=CC=C24 |
| InchiKey: | LBOJYSIDWZQNJS-CVEARBPZSA-N |
| Therapeutic Category: |
| Molecular Weight (dalton) | : | 221.303 |
| LogP | : | 3.1505 |
| Ring Count | : | 2 |
| Hydrogen Bond Acceptor Count | : | 1 |
| Hydrogen Bond Donor Count | : | 1 |
| Total Polar Surface Area | : | 12.03 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|---|---|---|
| Depression | Proto-oncogene protein c-fos (P01100) | Effects of the NMDA antaGOnist MK-801 on the expression of mRNA for GFAP and c-fos and demonstrated a marked reduction in the upregulation of these genes,application of high K+ concentrations to a limited area of the brain surface is known to trigger spreading depression [ ADR Type 2 ] | Analysis of c-Fos and glial fibrillary acidic protein (GFAP) expression following topical application of potassium chloride (KCl) to the brain surface |
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category
| Toxicity | Source |
|---|